This is the first clinical evidence to show that stimulating the programmed cell death protein 1 (PD1) inhibitory pathway is beneficial for rheumatologic disease.
Results of a Phase 2a clinical trial suggest that peresolimab, an antibody that stimulates the human death protein 1 (PD-1) pathway, could be a promising new approach for the treatment of rheumatoid arthritis.
Change from baseline in Disease Activity Score for 28 joints based on the C-reactive protein level was significantly greater for 700mg peresolimab vs placebo.
Only patients taking peresolimab 700 mg had a significantly greater change in Disease Activity Score in 28 Joints based on the C-reactive protein level (DAS28-CRP), compared with placebo after 12 weeks.
Lilly s peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.